Issues
Volume 205 Issue 4
News
Cancer control’s new STaR
Cancer Australia, in collaboration with leading national, state and territory health organisations and governments, has begun the ambitious STaR project to access and report national data on cancer Stage at diagnosis, Treatment and Recurrence. The project will greatly enhance our ability as a nation to understand variations in cancer outcomes by stage and treatment across population groups. While cancer registries based on the Australian population have been collecting and reporting high-quality data on cancer incidence and mortality for at least 30 years, there remains a lack of national data on the stage (severity of a cancer) when a patient is first diagnosed, the treatments subsequently applied and the frequency of cancer recurrence after treatment. The successful collection and reporting of STaR data, along with information already being collected on cancer incidence and mortality will provide, for the first time, important information across the journey of patients with cancer. With a better understanding of cancer outcomes by stage and treatment across population groups, we can more accurately address variations in practice. This will be especially valuable in variations in outcome across socio-demographic and culturally and linguistically diverse groups. The data may also assist in determining whether differences in survival can be explained by the treatment provided and patterns of care following diagnosis, which could identify areas for practice improvement. The knowledge gained will inform clinical best practice in cancer control, health services planning and public health policy. The STaR project will initially collect and report on the five cancers of highest incidence in Australia. Where available, data will be analysed by cancer type (site and histology), age and gender, Indigenous status, remoteness, socio-economic status and country of birth. In undertaking the STaR project, Cancer Australia is engaging with state and territory population-based cancer registries, as well as key cancer control stakeholders, including the Australian Institute of Health and Welfare, the Australasian Association of Cancer Registries and state and territory government health departments.
Elizabeth Coad
Perspectives
Behavioural innovation is key to improving the health of one million Australians living with type 2 diabetes
Policy, research and clinical practice need a paradigm shift, focused on human behaviour and psychology
Jane Speight
The Paleo diet and diabetes
Studies are inconclusive about the benefits of the Paleo diet in patients with type 2 diabetes
Sofianos Andrikopoulos
Obesity before pregnancy: new evidence and future strategies
Pre-conception weight control is important for both mother and child — and for Australia
Kirsten I Black · Adrienne Gordon
Medical education
Pitting and non-pitting oedema
The distinction is essential to determine aetiology and treatment
Elizabeth Whiting · Madeline E McCready
Poem
Editorials
The problem with modern endocrinology
Improved doctor–patient communications and more research are necessary
Jeffrey D Zajac
Preventing all the complications of hyperglycaemia: not a straightforward task
Individualised multifactorial treatment strategies are required to optimise outcomes
Aidan McElduff
Research
Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic control
Good glycaemic control is not sufficient for avoiding adverse outcomes for mother and child
Sally K Abell · Jacqueline A Boyle · Barbora de Courten · Michelle Knight · Sanjeeva Ranasinha · John Regan · Georgia Soldatos · Euan M Wallace · Sophia Zoungas · Helena J Teede
Low HIV testing rates among people with a sexually transmissible infection diagnosis in remote Aboriginal communities
Adhering to screening recommendations is essential to avoiding increased HIV infection rates in remote communities
James S Ward · Amalie Dyda · Skye McGregor · Alice Rumbold · Linda Garton · Basil Donovan · John M Kaldor · Rebecca J Guy
Short reports
Evaluation of the performance and outcomes for the first year of a diabetes rapid access clinic
Diabetes rapid access clinics (DRACs) have been identified by the New South Wales Agency for Clinical Innovation as a key component of an integrated diabetes model of care.1 This cost-effective model provides fast and comprehensive outpatient review and has been shown to circumvent hospital admission, decrease hospital length of stay and improve patient outcomes.2-5 Based on this approach, a nurse practitioner-led DRAC was established in February 2015 at Royal North Shore Hospital (RNSH) in Sydney as a pilot program to assess the suitability of the DRAC for scalability across the Northern Sydney Local Health District (NSLHD). The DRAC is an outpatient clinic, operating on weekdays, which adopts the principle that high-risk patients who present to the emergency department (ED) could be diverted from hospitalisation if they were well enough for outpatient management of their condition (Appendix). Patients are referred from general practice, the ED or the endocrinologist on call and require rapid review (within 72 hours) of complex diabetes problems, such as an episode (or episodes) of severe hypoglycaemia, recurring mild hypoglycaemia or hyperglycaemia not needing hospitalisation. We prospectively collected data during the first year since inception of the DRAC, with a particular focus on reasons for referral and cost evaluation. The study was approved by the NSLHD Human Research Ethics Committee (RESP/16/62). Within the first year of the DRAC pilot program at RNSH, 61 patients attended the clinic. About a quarter of these patients (n = 15) would have been hospitalised had they not been reviewed at the DRAC and they were successfully managed as outpatients. Although these patients met the criteria for admission, they were deemed appropriate for the DRAC by the endocrinologist on call. In addition, 26% of the patients were referred back to general practice, while the remainder required ongoing endocrinologist review. Most patients presented with hyperglycaemia-related problems (n = 40; 66%; Box), including 15 patients with newly diagnosed diabetes. A further 11 patients presented with severe hypoglycaemia. Within 30 days of review at the DRAC, one patient presented to the ED and required hospitalisation. Using a conservative costing approach, whereby patients were assumed to be uncomplicated with an average length of stay of 2.5 days (based on data from the NSLHD Performance Unit), the cost analysis demonstrated that for 15 patients for whom hospitalisation was avoided, about $46 700 would have been incurred in their inpatient stay. The DRAC was established through a restructure of existing services; however, if nursing costs associated with running the DRAC were included (about $23 400), the analysis showed that the cost of management in the clinic was half the cost of an inpatient stay (Box). A nurse practitioner-led DRAC was successfully established at a tertiary referral hospital in NSW. Our preliminary evaluation has demonstrated improved patient outcomes and assistance for general practice in managing ongoing outpatient diabetes-related problems. In addition, for a quarter of patients presenting to the DRAC, hospitalisation was prevented. Future directions include the expansion of the DRAC across the local health district and the incorporation of a “hotline” to assist general practitioners with urgent and complex diabetes management. Box – Royal North Shore Hospital Diabetes Rapid Access Clinic (DRAC) evaluation: overview of patient demographics and cost analysis data Patient demographic No. of patients* Patients seen (February – December 2015) 61 Male 42 Mean age, years (SD) 56 ± 16 Mean glycated haemoglobin value (SD) 9.7% ± 2.5% Mean duration of diabetes, years (SD) 13 ± 13 Type 1 diabetes 14 (23%) Type 2 diabetes 47 (77%) Reason for referral to DRAC Newly diagnosed type 1 diabetes 2 Newly diagnosed type 2 diabetes 13 Hyperglycaemia 25 Hypoglycaemia (severe) 11 Other 10 Cost analysis No. of hospitalisations prevented† 15 (25%) Hospitalisation cost per day $1245 Average length of stay, days 2.5 Total hospitalisation cost that would have been incurred $46 687.50 Cost of nursing at DRAC $23 339.52 Cost management difference $23 347.98 * Data are number of patients unless otherwise indicated. † One patient sent to the emergency department via DRAC — not diabetes related.
Neroli Newlyn · Rachel T McGrath · Gregory R Fulcher
Position statement
Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy
Part 1 of a position statement to update the 2000 guidelines and inform the recommended management of men with androgen deficiency
Bu B Yeap · Mathis Grossmann · Robert I McLachlan · David J Handelsman · Gary A Wittert · Ann J Conway · Bronwyn GA Stuckey · Douglas W Lording · Carolyn A Allan · Jeffrey D Zajac · Henry G Burger
Narrative review
Managing thyroid disease in general practice
Management is often straightforward, but there are pitfalls which may lead to misdiagnosis, overdiagnosis and inappropriate treatment
John P Walsh
Osteoporosis treatment: a missed opportunity
Effective treatment is available, but under-used, for a common and very costly health problem
Frances Milat · Peter R Ebeling
Letters
The Burns Registry of Australia and New Zealand: progressing the evidence base for burn care
In reply:
Heather Cleland
Lessons from the bedside: ketoacidosis and SGLT2 inhibitors
n/a
Yvonne Y Chow · Roisin Worsley · Duncan J Topliss
A caution regarding high-dose biotin therapy: misdiagnosis of hyperthyroidism in euthyroid patients
n/a
Christina M Trambas · Kenneth A Sikaris · Zhong X Lu
Correction
Careers
Mother and son
Professor Ingrid Scheffer and her son Eddie Cliff are passionate about encouraging other clinicians to engage in research to enrich their own lives as well as those of their patients …
Cate Swannell
Under pressure
Dr David Wilkinson, OAM, works in a field not many of his colleagues recognise or respect …
Cate Swannell
Feel better by planting trees and taking up yoga
Steve McDonald · Tari Turner
News briefs
Cate Swannell
Streamlining ethics review for multisite quality and safety initiatives: national bariatric surgery registry experience
Wendy A Brown · Brittany R Smith · Melissa Boglis · Dianne L Brown · Margaret Anderson · Paul E O'Brien · John J McNeil · Ian D Caterson
The inequitable burden of group A streptococcal diseases in Indigenous Australians
Philippa J May · Asha C Bowen · Jonathan R Carapetis
News briefs
Cate Swannell
Time to bury “hypertension”
Mark R Nelson
“Congenital heart health”: how psychological care can make a difference
Nadine A Kasparian · David S Winlaw · Gary F Sholler